Hypermutator Pseudomonas aeruginosa Exploits Multiple Genetic Pathways To Develop Multidrug Resistance during Long-Term Infections in the Airways of Cystic Fibrosis Patients.
| Title: | Hypermutator Pseudomonas aeruginosa Exploits Multiple Genetic Pathways To Develop Multidrug Resistance during Long-Term Infections in the Airways of Cystic Fibrosis Patients. |
|---|---|
| Authors: | Colque CA; Universidad Nacional de Córdoba, Facultad de Ciencias Químicas, Departamento de Química Biológica Ranwel Caputto, Córdoba, Argentina.; CONICET, Universidad Nacional de Córdoba, Centro de Investigaciones en Química Biológica de Córdoba (CIQUIBIC), Córdoba, Argentina.; Albarracín Orio AG; Universidad Nacional de Córdoba, Facultad de Ciencias Químicas, Departamento de Química Biológica Ranwel Caputto, Córdoba, Argentina.; CONICET, Universidad Nacional de Córdoba, Centro de Investigaciones en Química Biológica de Córdoba (CIQUIBIC), Córdoba, Argentina.; IRNASUS, CONICET, Universidad Católica de Córdoba, Facultad de Ciencias Agropecuarias, Córdoba, Argentina.; Feliziani S; Universidad Nacional de Córdoba, Facultad de Ciencias Químicas, Departamento de Química Biológica Ranwel Caputto, Córdoba, Argentina.; CONICET, Universidad Nacional de Córdoba, Centro de Investigaciones en Química Biológica de Córdoba (CIQUIBIC), Córdoba, Argentina.; Marvig RL; Center for Genomic Medicine, Rigshospitalet, Copenhagen, Denmark.; Tobares AR; Universidad Nacional de Córdoba, Facultad de Ciencias Químicas, Departamento de Química Biológica Ranwel Caputto, Córdoba, Argentina.; CONICET, Universidad Nacional de Córdoba, Centro de Investigaciones en Química Biológica de Córdoba (CIQUIBIC), Córdoba, Argentina.; Johansen HK; Department of Clinical Microbiology, Rigshospitalet, Copenhagen, Denmark.; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.; Molin S; Novo Nordisk Foundation Centre for Biosustainability, Technical University of Denmark, Lyngby, Denmark.; Smania AM; Universidad Nacional de Córdoba, Facultad de Ciencias Químicas, Departamento de Química Biológica Ranwel Caputto, Córdoba, Argentina asmania@fcq.unc.edu.ar.; CONICET, Universidad Nacional de Córdoba, Centro de Investigaciones en Química Biológica de Córdoba (CIQUIBIC), Córdoba, Argentina. |
| Source: | Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2020 Apr 21; Vol. 64 (5). Date of Electronic Publication: 2020 Apr 21 (Print Publication: 2020). |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Language: | English |
| Journal Info: | Publisher: American Society for Microbiology Country of Publication: United States NLM ID: 0315061 Publication Model: Electronic-Print Cited Medium: Internet ISSN: 1098-6596 (Electronic) Linking ISSN: 00664804 NLM ISO Abbreviation: Antimicrob Agents Chemother Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Washington, American Society for Microbiology |
| MeSH Terms: | Anti-Bacterial Agents/*pharmacology ; Cystic Fibrosis/*microbiology ; Drug Resistance, Multiple, Bacterial/*genetics ; Pseudomonas aeruginosa/*drug effects ; Pseudomonas aeruginosa/*genetics; Bacterial Proteins/genetics ; Cystic Fibrosis/pathology ; Mutation/genetics ; Penicillin-Binding Proteins/genetics ; Peptidoglycan Glycosyltransferase/genetics ; Pseudomonas Infections/drug therapy ; Pseudomonas aeruginosa/isolation & purification ; Respiratory System/microbiology ; beta-Lactam Resistance/genetics ; beta-Lactamases/genetics ; Humans |
| Abstract: | Pseudomonas aeruginosa exploits intrinsic and acquired resistance mechanisms to resist almost every antibiotic used in chemotherapy. Antimicrobial resistance in P. aeruginosa isolates recovered from cystic fibrosis (CF) patients is further enhanced by the occurrence of hypermutator strains, a hallmark of chronic infections in CF patients. However, the within-patient genetic diversity of P. aeruginosa populations related to antibiotic resistance remains unexplored. Here, we show the evolution of the mutational resistome profile of a P. aeruginosa hypermutator lineage by performing longitudinal and transversal analyses of isolates collected from a CF patient throughout 20 years of chronic infection. Our results show the accumulation of thousands of mutations, with an overall evolutionary history characterized by purifying selection. However, mutations in antibiotic resistance genes appear to have been positively selected, driven by antibiotic treatment. Antibiotic resistance increased as infection progressed toward the establishment of a population constituted by genotypically diversified coexisting sublineages, all of which converged to multidrug resistance. These sublineages emerged by parallel evolution through distinct evolutionary pathways, which affected genes of the same functional categories. Interestingly, ampC and ftsI, encoding the β-lactamase and penicillin-binding protein 3, respectively, were found to be among the most frequently mutated genes. In fact, both genes were targeted by multiple independent mutational events, which led to a wide diversity of coexisting alleles underlying β-lactam resistance. Our findings indicate that hypermutators, apart from boosting antibiotic resistance evolution by simultaneously targeting several genes, favor the emergence of adaptive innovative alleles by clustering beneficial/compensatory mutations in the same gene, hence expanding P. aeruginosa strategies for persistence.; (Copyright © 2020 American Society for Microbiology.) |
| References: | Int J Antimicrob Agents. 2019 May;53(5):620-628. (PMID: 30664925); Science. 2000 May 19;288(5469):1251-4. (PMID: 10818002); Nature. 2016 Jan 21;529(7586):336-43. (PMID: 26791724); Bioinformatics. 2009 Aug 15;25(16):2078-9. (PMID: 19505943); BMC Genomics. 2015;16 Suppl 8:S1. (PMID: 26110438); Antimicrob Agents Chemother. 2005 Aug;49(8):3382-6. (PMID: 16048951); Front Microbiol. 2017 Feb 17;8:246. (PMID: 28261193); Elife. 2019 Jan 08;8:. (PMID: 30616716); Microbiology. 2011 Apr;157(Pt 4):937-944. (PMID: 21292748); Antimicrob Agents Chemother. 1999 Feb;43(2):400-2. (PMID: 9925544); Proc Natl Acad Sci U S A. 2006 May 30;103(22):8487-92. (PMID: 16687478); Antimicrob Agents Chemother. 2012 Aug;56(8):4519-21. (PMID: 22644032); Mol Biol Evol. 2017 Sep 1;34(9):2229-2244. (PMID: 28541480); Antimicrob Agents Chemother. 2019 Mar 27;63(4):. (PMID: 30745381); J Struct Biol. 2010 Dec;172(3):305-10. (PMID: 20691272); Diagn Microbiol Infect Dis. 2014 Mar;78(3):271-6. (PMID: 24412662); Antimicrob Agents Chemother. 2014 Jun;58(6):3091-9. (PMID: 24637685); Microbiologyopen. 2015 Feb;4(1):121-35. (PMID: 25450797); Future Microbiol. 2017 Dec;12:1445-1448. (PMID: 29068237); PLoS Pathog. 2009 Mar;5(3):e1000353. (PMID: 19325877); mBio. 2014 Apr 22;5(2):e01068. (PMID: 24757215); J Cyst Fibros. 2008 Sep;7(5):391-7. (PMID: 18358794); Bioessays. 2000 Dec;22(12):1057-66. (PMID: 11084621); Antimicrob Agents Chemother. 2018 May 25;62(6):. (PMID: 29581123); J Bacteriol. 2008 Dec;190(24):7910-7. (PMID: 18849421); Trends Microbiol. 2011 Aug;19(8):419-26. (PMID: 21664819); Drugs. 2014 Jan;74(1):31-51. (PMID: 24352909); Genome Biol. 2004;5(2):R12. (PMID: 14759262); Antimicrob Agents Chemother. 2015 Oct;59(10):6248-55. (PMID: 26248364); J Infect Dis. 2009 Jul 1;200(1):118-30. (PMID: 19459782); J Clin Microbiol. 2008 Oct;46(10):3491-3. (PMID: 18685006); Antimicrob Agents Chemother. 2016 Jun 20;60(7):4229-36. (PMID: 27139485); J Biol Chem. 2004 Mar 5;279(10):8761-8. (PMID: 14679195); Genetics. 1999 Jun;152(2):485-93. (PMID: 10353893); Int J Antimicrob Agents. 2015 May;45(5):529-32. (PMID: 25735764); Thorax. 2017 Jan;72(1):40-47. (PMID: 27325751); Front Microbiol. 2011 Apr 05;2:65. (PMID: 21747788); J Bacteriol. 2002 Sep;184(18):5036-44. (PMID: 12193619); Antimicrob Agents Chemother. 1996 Sep;40(9):2021-8. (PMID: 8878574); Clin Infect Dis. 2003 Nov 1;37(9):1201-9. (PMID: 14557965); Genetics. 2006 Jan;172(1):611-26. (PMID: 16157667); J Infect Dis. 2007 Jan 1;195(1):70-80. (PMID: 17152010); J Antimicrob Chemother. 2012 Nov;67(11):2640-4. (PMID: 22782487); mBio. 2010 Sep 21;1(4):. (PMID: 20856824); Antimicrob Agents Chemother. 2013 May;57(5):2204-15. (PMID: 23459479); PLoS Genet. 2008 Jan;4(1):e2. (PMID: 18193944); Diagn Microbiol Infect Dis. 2014 Apr;78(4):443-8. (PMID: 24492025); Antimicrob Agents Chemother. 2018 Jan 25;62(2):. (PMID: 29133559); Antimicrob Agents Chemother. 2015 Jan;59(1):427-36. (PMID: 25367914); Nat Rev Microbiol. 2012 Dec;10(12):841-51. (PMID: 23147702); Antimicrob Agents Chemother. 2013 Dec;57(12):5987-93. (PMID: 24041903); Clin Microbiol Rev. 2002 Apr;15(2):194-222. (PMID: 11932230); Antimicrob Agents Chemother. 2005 Nov;49(11):4567-75. (PMID: 16251297); mBio. 2015 Sep 01;6(5):e00981-15. (PMID: 26330513); PLoS Genet. 2014 Oct 16;10(10):e1004651. (PMID: 25330091); mBio. 2018 Dec 11;9(6):. (PMID: 30538183); PLoS One. 2010 Sep 10;5(9):. (PMID: 20844762); Genome Res. 2008 May;18(5):821-9. (PMID: 18349386); Nat Genet. 2011 May;43(5):491-8. (PMID: 21478889); mBio. 2014 Sep 16;5(5):e01592-14. (PMID: 25227464); Chem Biol Drug Des. 2015 Jan;85(1):56-78. (PMID: 25393203); Antimicrob Agents Chemother. 2016 Nov 21;60(12):7415-7423. (PMID: 27736752); Microbiology. 2007 May;153(Pt 5):1445-1454. (PMID: 17464058); J Bacteriol. 2005 Aug;187(15):5341-6. (PMID: 16030228); Trends Microbiol. 2016 May;24(5):327-337. (PMID: 26946977); Antimicrob Agents Chemother. 1994 Sep;38(9):1944-52. (PMID: 7811002); Evol Med Public Health. 2014 Dec 21;2015(1):4-12. (PMID: 25535278); Nature. 1997 Jun 12;387(6634):700-2. (PMID: 9192893); J Mol Biol. 2012 Mar 9;416(5):697-712. (PMID: 22300763); Antimicrob Agents Chemother. 2016 Oct 21;60(11):6726-6734. (PMID: 27572404); Nat Genet. 2015 Jan;47(1):57-64. (PMID: 25401299); Antimicrob Agents Chemother. 2018 Feb 23;62(3):. (PMID: 29263076); Int J Med Microbiol. 2010 Dec;300(8):563-72. (PMID: 20837399); J Bacteriol. 1997 Jul;179(13):4382-90. (PMID: 9209057); Antimicrob Agents Chemother. 2012 Dec;56(12):6212-22. (PMID: 23006746); Eur Respir J. 2017 May 19;49(5):. (PMID: 28526799); PLoS Genet. 2013;9(9):e1003741. (PMID: 24039595); Antimicrob Agents Chemother. 2016 Jan 04;60(3):1767-78. (PMID: 26729493); PLoS One. 2012;7(10):e46688. (PMID: 23056405); Antimicrob Agents Chemother. 2013 May;57(5):2243-51. (PMID: 23459488); Antimicrob Agents Chemother. 2014;58(1):221-8. (PMID: 24145539); Microb Pathog. 2014 Dec;77:36-41. (PMID: 25448466); Genetics. 2010 Dec;186(4):1345-54. (PMID: 20876562); J Bacteriol. 2007 Jul;189(13):4561-8. (PMID: 17449606); Antimicrob Agents Chemother. 2011 Dec;55(12):5761-9. (PMID: 21968359); Bioinformatics. 2010 Mar 15;26(6):722-9. (PMID: 20144947); Drug Resist Updat. 2015 Jul-Aug;21-22:41-59. (PMID: 26304792); Mol Microbiol. 2007 Apr;64(2):547-59. (PMID: 17493134); Philos Trans R Soc Lond B Biol Sci. 2010 Apr 27;365(1544):1255-63. (PMID: 20308101); Antimicrob Agents Chemother. 2011 Mar;55(3):1211-21. (PMID: 21149619); Antimicrob Agents Chemother. 2013 Jan;57(1):110-9. (PMID: 23070157); Antimicrob Agents Chemother. 2005 Jun;49(6):2276-82. (PMID: 15917521); Curr Biol. 2007 Mar 6;17(5):385-94. (PMID: 17331728); Proc Natl Acad Sci U S A. 2010 Dec 21;107(51):22002-7. (PMID: 21135211); J Antimicrob Chemother. 2018 Dec 1;73(12):3322-3331. (PMID: 30189050); Microbiology. 2007 Jan;153(Pt 1):225-37. (PMID: 17185551); Antimicrob Agents Chemother. 2009 Apr;53(4):1552-60. (PMID: 19188376); Antimicrob Agents Chemother. 2006 May;50(5):1623-7. (PMID: 16641427); Antimicrob Agents Chemother. 2000 Mar;44(3):583-9. (PMID: 10681322); Antimicrob Agents Chemother. 2009 May;53(5):1987-97. (PMID: 19258280); Antimicrob Agents Chemother. 2018 Jul 27;62(8):. (PMID: 29844045); J Bacteriol. 2012 Sep;194(18):4857-66. (PMID: 22753054); Front Microbiol. 2018 Apr 06;9:685. (PMID: 29681898); Clin Microbiol Rev. 2009 Oct;22(4):582-610. (PMID: 19822890); J Antimicrob Chemother. 2014 Jul;69(7):1804-14. (PMID: 24603963); PLoS One. 2015 Jul 29;10(7):e0133842. (PMID: 26221722); Antimicrob Agents Chemother. 2017 Oct 24;61(11):. (PMID: 28874376); Nat Protoc. 2009;4(7):1073-81. (PMID: 19561590); Sci Rep. 2017 Jul 17;7(1):5555. (PMID: 28717172); mBio. 2017 Oct 31;8(5):. (PMID: 29089424); Proc Natl Acad Sci U S A. 2011 May 3;108(18):7481-6. (PMID: 21518885) |
| Contributed Indexing: | Keywords: Pseudomonas aeruginosa; ampC; cystic fibrosis; ftsI; hypermutability; multidrug resistance |
| Substance Nomenclature: | 0 (Anti-Bacterial Agents); 0 (Bacterial Proteins); 0 (Penicillin-Binding Proteins); EC 2.4.1.129 (Peptidoglycan Glycosyltransferase); EC 3.5.2.6 (AmpC beta-lactamases); EC 3.5.2.6 (beta-Lactamases) |
| Entry Date(s): | Date Created: 20200220 Date Completed: 20210322 Latest Revision: 20210322 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC7179616 |
| DOI: | 10.1128/AAC.02142-19 |
| PMID: | 32071060 |
| Database: | MEDLINE |
Journal Article; Research Support, Non-U.S. Gov't